What outcome after the prescription of neoadjuvant chemotherapy in lung cancer
作者： Mohamed-Sadok Boudaya , Hanène Smadhi , Adel Marghli , Fatma Charmiti , Sonia Ouerghi
关键词:
摘要: BackgroundThe treatment of patients with locally advanced non-small-cell lung cancer is controversial. Surgery remains the gold standard, even in this group. Neoadjuvant chemotherapy could allow surgical resection initially judged inoperable.MethodsFrom January 2009 to May 2010, neoadjuvant was indicated 27 NSCLC (25 men, 2 women). Their mean age 65 years. The stages were: IIB 5, IIIA 17 (6 stage IIIAN2), IIIB 2, and IV 3.Results23 received chemotherapy, refused induction treatment, had impaired status. regimen gemcitabine-cisplatin vinorelbine-cisplatin 6. Only 5 underwent complete after induction: 1 IIB, IIIAN0, IIIB, (1 operated brain metastasis, adrenal metastasis). Surgical not achieved 18 because progressive disea...
sagepub.com
sci-hub.se 参考文章(23)
Ramón Rami-Porta, Vanessa Bolejack, John Crowley, David Ball, Jhingook Kim, Gustavo Lyons, Thomas Rice, Kenji Suzuki, Charles F Thomas Jr, William D Travis, Yi-Long Wu, Prognostic Factors Committee, None, The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer Journal of Thoracic Oncology. ,vol. 2, pp. 990- 1003 ,(2007) , 10.1097/JTO.0B013E31811F4703
K S Albain, V W Rusch, J J Crowley, T W Rice, A T Turrisi, J K Weick, V A Lonchyna, C A Presant, R J McKenna, D R Gandara, Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. Journal of Clinical Oncology. ,vol. 13, pp. 1880- 1892 ,(1995) , 10.1200/JCO.1995.13.8.1880
L Crinò, G Scagliotti, M Marangolo, F Figoli, M Clerici, F De Marinis, F Salvati, G Cruciani, L Dogliotti, F Pucci, A Paccagnella, V Adamo, G Altavilla, P Incoronato, M Trippetti, A M Mosconi, A Santucci, S Sorbolini, C Oliva, M Tonato, Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 15, pp. 297- 303 ,(1997) , 10.1200/JCO.1997.15.1.297
Georgios Stamatis, Wilfried Eberhard, Christoph Pöttgen, Surgery after multimodality treatment for non-small-cell lung cancer. Lung Cancer. ,vol. 45, ,(2004) , 10.1016/J.LUNGCAN.2004.07.984
Marc Riquet, Patrick Bagan, Françoise Le Pimpec Barthes, Eugeniu Banu, Florian Scotte, Christophe Foucault, Antoine Dujon, Claire Danel, Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. The Annals of Thoracic Surgery. ,vol. 84, pp. 1818- 1824 ,(2007) , 10.1016/J.ATHORACSUR.2007.07.015
Frederic W. Grannis, Is primary resection of stage IIIA lung cancer futile The Annals of Thoracic Surgery. ,vol. 86, pp. 353- 354 ,(2008) , 10.1016/J.ATHORACSUR.2008.01.025
Igor Brichkov, Steven M. Keller, Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non–Small Cell Lung Cancer Thoracic Surgery Clinics. ,vol. 18, pp. 381- 391 ,(2008) , 10.1016/J.THORSURG.2008.08.003
Domenico Galetta, Alfredo Cesario, Stefano Margaritora, Venanzio Porziella, Giuseppe Macis, Rolando M D'Angelillo, Lucio Trodella, Silvia Sterzi, Pierluigi Granone, Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach The Annals of Thoracic Surgery. ,vol. 76, pp. 1802- 1809 ,(2003) , 10.1016/S0003-4975(03)01063-4
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74